Evercore ISI upgraded Charles River (CRL) to Outperform from In Line with a price target of $170, up from $135, following Q1 earnings and the cooperation agreement with Elliott. Reasons for the upgrade following today’s print include the fact that bookings reaccelerated quarter-over-quarter for the first time since 2022, updated disclosure on NAMs after last month’s FDA recommendation to shift away from animal-based testing for mAbs, the company’s “enviable market position as a key preclinical development partner” and valuation, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue